NellOne Therapeutics Inc. believes it can help patients restore muscle mass and function thanks to a gene called Nell-1. If early studies bear out, the company’s research could yield protein therapeutics capable of regenerating muscle around joint replacements and even in hearts damaged by heart attacks. An in vitro study of heart muscle cells showed the protein could protect those cells and prevent them from dying in the very kind of low-oxygen situation that typifi es the conditions that heart muscle cells encounter during a heart attack. NellOne has chosen to develop its technology as a wound-healing therapy initially, because that research is farthest along and the path to market is shorter than for a cardiovascular indication.
10702 Murdock Road
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
Deal Snapshot: Lilly is the third company to sign a licensing deal for STAC-BBB with Sangamo, which also aims to secure a deal for its Fabry disease program in the second quarter.
The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
